EXPERTISE THAT FUELS TRANSFORMATIVE CARE

Originally founded in San Diego by four scientists with deep roots in endocrinology, GPCR biology, and medicinal chemistry, Crinetics has a world-class research and development team committed to transforming endocrine disease treatment, from discovery through commercialization.  Crinetics is unique in the biopharmaceutical industry, with a focus on the overlap of unmet medical needs in endocrinology, endocrine-driven oncology, and the pharmacology of G-protein-coupled receptors (GPCRs).  

Since our inception, we have built unique capabilities by cultivating a deep bench of leading scientists, researchers, and clinicians. Our discovery efforts have fueled a wholly owned pipeline, with 10 disclosed programs across several therapeutic areas. To increase the likelihood of clinical success, we prioritize biomarker validation from the earliest stages of discovery through approval, ensuring our endocrine and endocrine-rooted candidates are guided by clear, measurable indicators of target engagement and efficacy. 

At Crinetics, patients are more than recipients of our therapies; they are active partners in shaping them. Their insights guide every stage of development, helping us design smarter science, more relevant trials, and ultimately, treatments that make a meaningful difference in real life. 

GPCRs are proteins in cell membranes that detect and respond to external molecules  such as light, odors, neurotransmitters, and hormones. In endocrinology, GPCRs are activated by neuropeptides and other hormones that carry out specific signaling pathways in the cell. Excess or deficiency of these neuropeptides can result in the symptoms and signs associated with many endocrinological disorders.  

Explore our approach